Sonnet Biotherapeutics Holdings Inc expected to post a loss of 90 cents a share - Earnings Preview
09/02/2024 13:09
* Sonnet Biotherapeutics Holdings Inc SONN.OQ SONN.O is
expected to report resultson February 12 (estimated) for the
period ending December 31 2023
* The Princeton New Jersey-based company is expected to
report
revenue of $18 thousand, according to the mean estimate from 2
analysts, based on LSEG data.
* LSEG's mean analyst estimate for Sonnet Biotherapeutics
Holdings Inc is for a loss of 90 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Sonnet
Biotherapeutics Holdings Inc is $32.50, above its last closing
price of $1.47.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -2.60 -4.09 -2.09 Beat 48.9
Jun. 30 2023 -6.82 -2.86 Beat 58.1
Mar. 31 2023 -10.29 -10.89 -7.48 Beat 31.3
Dec. 31 2022 -24.20 -24.20 -17.60 Beat 27.3
Sep. -33.22 -33.22 -36.74 Missed -10.6
30 2022
Jun. 30 2022 -43.31 -43.12 -40.04 Beat 7.1
Mar. 31 2022 -40.04 -36.96 -43.12 Missed -16.7
Dec. 31 2021 -58.56 -58.52 -30.80 Beat 47.4
This summary was machine generated February 9 at 13:08 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)